Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, Wegovy is a once-weekly injectable using a user-friendly FlexTouch pen ...

Novo Nordisk is partnering with WeightWatchers to offer consumers access to Wegovy after it abruptly ended its collaboration with Hims & Hers.

June 26 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1. Under the deal ...

Novo Nordisk and Hims & Hers just announced a partnership in April. Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for ...

Drugmaker Novo Nordisk said on Monday it would halt its Wegovy weight-loss drug agreement with U.S. telehealth company Hims & Hers Health, pushing Hims shares down 31% in morning trading. The two ...

Novo Nordisk has cut ties with Hims & Hers Health, alleging that the latter company has engaged in deceptive marketing tactics and illegal compounding, risking patient safety.Novo Nordisk ...

Novo Nordisk (NVO) partners with WeightWatchers to expand access to Wegovy through NovoCare Pharmacy after ending a deal with Hims & Hers (HIMS). Read more here.

Novo Nordisk plans to expand access to Wegovy through a collaboration with WeightWatchers, days after ending a partnership with telehealth firm Hims & Hers to sell the weight-loss drug.

Novo Nordisk is expanding access to its drug Wegovy through a new partnership with WeightWatchers, days after cutting ties with telehealth firm Hims & Hers. Starting July 1, WeightWatchers will ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with weight-loss drugmaker Novo Nordisk abruptly ended.

Novo Nordisk (NVO) launches its blockbuster weight-loss drug Wegovy in India, shortly after rival Eli Lilly (LLY) introduced its popular weight loss/diabetes therapy Mounjaro in the country this ...